{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:06:36Z","timestamp":1793743596536,"version":"4.6.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,7]]},"DOI":"10.1093\/jnci\/djr242","type":"journal-article","created":{"date-parts":[[2011,7,9]],"date-time":"2011-07-09T00:26:12Z","timestamp":1310171172000},"page":"1299-1309","source":"Crossref","is-referenced-by-count":538,"title":["Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"103","author":[{"given":"Eitan","family":"Amir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bostjan","family":"Seruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Niraula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,8,22]]},"reference":[{"issue":"24","key":"key\n\t\t\t\t20170521000101_bib1","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t20170521000101_bib2","doi-asserted-by":"crossref","first-page":"vii10","DOI":"10.1093\/annonc\/mdl941","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial","volume":"17","author":"Boccardo","year":"2006","journal-title":"Ann Oncol."},{"issue":"5","key":"key\n\t\t\t\t20170521000101_bib3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol."},{"issue":"9484","key":"key\n\t\t\t\t20170521000101_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years\u2019 adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet."},{"issue":"1","key":"key\n\t\t\t\t20170521000101_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol."},{"issue":"3","key":"key\n\t\t\t\t20170521000101_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","article-title":"Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol."},{"issue":"6","key":"key\n\t\t\t\t20170521000101_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.2008.19.5594","article-title":"Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes","volume":"27","author":"Seruga","year":"2009","journal-title":"J Clin Oncol."},{"issue":"6","key":"key\n\t\t\t\t20170521000101_bib8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.bjc.6605231","article-title":"Tamoxifen: the drug that came in from the cold","volume":"101","author":"Hughes-Davies","year":"2009","journal-title":"Br J Cancer."},{"issue":"20","key":"key\n\t\t\t\t20170521000101_bib9","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1200\/JCO.2010.28.3564","article-title":"Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more?","volume":"28","author":"Seruga","year":"2010","journal-title":"J Clin Oncol."},{"issue":"3","key":"key\n\t\t\t\t20170521000101_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials."},{"key":"key\n\t\t\t\t20170521000101_bib11","volume-title":"Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4 2 5","author":"Deeks"},{"issue":"7305","key":"key\n\t\t\t\t20170521000101_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","article-title":"Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests","volume":"323","author":"Deeks","year":"2001","journal-title":"BMJ."},{"issue":"9561","key":"key\n\t\t\t\t20170521000101_bib13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet."},{"issue":"2","key":"key\n\t\t\t\t20170521000101_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10549-010-0888-x","article-title":"Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study","volume":"121","author":"Aihara","year":"2010","journal-title":"Breast Cancer Res Treat."},{"issue":"9762","key":"key\n\t\t\t\t20170521000101_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet."},{"issue":"6","key":"key\n\t\t\t\t20170521000101_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jclinepi.2008.08.005","article-title":"Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials","volume":"62","author":"Tsang","year":"2009","journal-title":"J Clin Epidemiol."},{"issue":"2","key":"key\n\t\t\t\t20170521000101_bib17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cncr.23171","article-title":"Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials","volume":"112","author":"Cuppone","year":"2008","journal-title":"Cancer."},{"key":"key\n\t\t\t\t20170521000101_bib18","volume-title":"Anastrozole: Full Prescribing Information","author":"Food and Drug Administration"},{"issue":"6","key":"key\n\t\t\t\t20170521000101_bib19","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1073\/pnas.051003698","article-title":"Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase","volume":"98","author":"Nathan","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"36","key":"key\n\t\t\t\t20170521000101_bib20","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1200\/JCO.2007.12.1665","article-title":"Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial","volume":"25","author":"Mouridsen","year":"2007","journal-title":"J Clin Oncol."},{"issue":"11","key":"key\n\t\t\t\t20170521000101_bib21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.7326\/0003-4819-115-11-860","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women","volume":"115","author":"Love","year":"1991","journal-title":"Ann Intern Med."},{"issue":"11","key":"key\n\t\t\t\t20170521000101_bib22","first-page":"3191","article-title":"The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women","volume":"80","author":"Grey","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"issue":"17","key":"key\n\t\t\t\t20170521000101_bib23","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/jnci\/85.17.1398","article-title":"Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group","volume":"85","author":"Rutqvist","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"7011","key":"key\n\t\t\t\t20170521000101_bib24","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/bmj.311.7011.977","article-title":"Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group","volume":"311","author":"McDonald","year":"1995","journal-title":"BMJ."},{"issue":"17","key":"key\n\t\t\t\t20170521000101_bib25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst."},{"issue":"12","key":"key\n\t\t\t\t20170521000101_bib26","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","article-title":"Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial","volume":"26","author":"Mamounas","year":"2008","journal-title":"J Clin Oncol."},{"issue":"24","key":"key\n\t\t\t\t20170521000101_bib27","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jnci\/djm246","article-title":"Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a","volume":"99","author":"Jakesz","year":"2007","journal-title":"J Natl Cancer Inst."},{"issue":"20","key":"key\n\t\t\t\t20170521000101_bib28","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/86.20.1534","article-title":"Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment","volume":"86","author":"Love","year":"1994","journal-title":"J Natl Cancer Inst."},{"issue":"10","key":"key\n\t\t\t\t20170521000101_bib29","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1212\/WNL.37.10.1667","article-title":"Hypercoagulability in acute stroke: prognostic significance","volume":"37","author":"Landi","year":"1987","journal-title":"Neurology."},{"issue":"8","key":"key\n\t\t\t\t20170521000101_bib30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/01.STR.21.8.1111","article-title":"Hematologic disorders and ischemic stroke. A selective review","volume":"21","author":"Hart","year":"1990","journal-title":"Stroke."},{"key":"key\n\t\t\t\t20170521000101_bib31","doi-asserted-by":"crossref","first-page":"403s","DOI":"10.1158\/0008-5472.SABCS10-P5-13-03","article-title":"The influences of co-morbidities and age on risk of death without recurrence: a retrospective analysis of the ATAC trial","volume":"70","author":"Ring","year":"2010","journal-title":"Cancer Res."},{"issue":"13","key":"key\n\t\t\t\t20170521000101_bib32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jnci\/djq211","article-title":"Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer","volume":"102","author":"Garber","year":"2010","journal-title":"J Natl Cancer Inst."},{"issue":"8","key":"key\n\t\t\t\t20170521000101_bib33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5694\/j.1326-5377.2003.tb05621.x","article-title":"Adverse event reporting in clinical trials: room for improvement","volume":"179","author":"Liauw","year":"2003","journal-title":"Med J Aust."}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/103\/17\/1299\/17311159\/djr242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T02:35:57Z","timestamp":1592706957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djr242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,22]]},"references-count":33,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2011,8,22]]},"published-print":{"date-parts":[[2011,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djr242","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13357185.14726525","asserted-by":"object"}]},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,22]]}}}